Advertisement
Advertisement
XNCR
Xencor, Inc.
20.81
USDSponsored
+0.81
+4.05%
Aug 07, 15:59 UTC -4
Closed
After-Market
20.86
+0.05
+0.24%
XNCR Earnings Reports
Positive Surprise Ratio
XNCR beat 31 of 43 last estimates.
72%
Next Report
Date of Next Report
Nov 03, 2026
Estimate for Q3 26 (Revenue/ EPS)
$24.17M
/-$0.79
Implied change from Q2 26 (Revenue/ EPS)
-52.82%
/+182.14%
Implied change from Q3 25 (Revenue/ EPS)
+15.09%
/+887.50%
Xencor, Inc. earnings per share and revenue
On Aug 05, 2026, XNCR reported earnings of -0.28 USD per share (EPS) for Q2 26, beating the estimate of -0.85 USD, resulting in a 65.93% surprise. Revenue reached 51.22 million, compared to an expected 19.30 million, with a 165.39% difference. The market reacted with a +0.81% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 11 analysts forecast an EPS of -0.79 USD, with revenue projected to reach 24.17 million USD, implying an increase of 182.14% EPS, and decrease of -52.82% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.74
Actual
$1.92
Surprise
+9.75%
Cronos Group Inc. Common Share
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.00
Actual
$0.03
Surprise
0.00%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.36
Actual
$0.31
Surprise
-14.62%
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.35
Actual
-$0.71
Surprise
-98.88%
Avita Medical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.25
Surprise
+14.50%
electroCore, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.33
Surprise
+23.40%
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.36
Actual
-$0.39
Surprise
-5.95%
FAQ
What were Xencor, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Xencor, Inc. reported EPS of -$0.28, beating estimates by 65.93%, and revenue of $51.22M, 165.39% above expectations.
How did the market react to Xencor, Inc.'s Q2 2026 earnings?
The stock price moved up 0.81%, changed from $19.84 before the earnings release to $20.00 the day after.
When is Xencor, Inc. expected to report next?
The next earning report is scheduled for Nov 03, 2026.
What are the forecasts for Xencor, Inc.'s next earnings report?
Based on 11
analysts, Xencor, Inc. is expected to report EPS of -$0.79 and revenue of $24.17M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement